ARMONICA TECHNOLOGIES INC.

Company Overview

Armonica Technologies Inc. is developing a long-read sequencing platform based on nano-structure devices. The technology is designed to read native NDA with epigenetic modifications and is label- and amplification-free.

The sequencing platform controls the speed of nucleic acid transport through nanochannels and reads single-base spectra optically, without any need for library preparations of biological manipulation. It also directly detects epigenetic nucleotide modifications.

In August 2022, the company received an award of a follow-on Phase II SBIR grant from the NIH’s National Human Genome Research Institute for “Single molecule DNA/RNA transport and Raman scattering readout in a coupled nanochannel/nanopore sequencing system.” In March 2021, the company received an SBIR grant from the NIH’s National Human Genome Research Institute for “Single molecule DNA/RNA transport and Raman scattering readout in a coupled nanochannel/nanopore sequencing system.

Company's Business Segments

• Sequencing Platform : This segment employs Nanochannels to deliver Single Nucleic Acid Molecules through Nanopores for Optical readout by Raman Spectroscopy, enabling direct reading of characteristic Nucleotide, Epigenetic Signatures.